Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-escalation Phase I/IIa Study to Evaluate the Safety and Efficacy of EXG102-031 Intraocular Injection in Participants With Neovascular Age-related Macular Degeneration（wAMD）

NCT06183814 is registered in ClinicalTrials.gov with Guangzhou Jiayin Biotech Ltd as lead sponsor.

NCT NCT06183814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06183814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-escalation Phase I/IIa Study to Evaluate the Safety and Efficacy of EXG102-031 Intraocular Injection in Participants With Neovascular Age-related Macular Degeneration（wAMD）
Lead sponsor
Guangzhou Jiayin Biotech Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 12, 2023
Completion date
December 31, 2025
Enrollment
42 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration